A number of revised COVID-19 vaccines have been created as of May 2025 to address new variations and offer improved protection. Below is a summary of the most recent vaccines along with their names:
pdated COVID-19 Vaccines for 2024–2025
1. Comirnaty (2024–2025 Formula)
- Manufacturer: Pfizer-BioNTech
- Type: mRNA vaccine
- Target: Omicron variant KP.2
- Approval Status: Fully approved for individuals aged 12 and older; emergency use authorization (EUA) for children aged 6 months through 11 years.
2. Spikevax (2024–2025 Formula)
- Manufacturer: Moderna
- Type: mRNA vaccine
- Target: Omicron variant KP.2
- Approval Status: Fully approved for individuals aged 12 and older; EUA for children aged 6 months through 11 years.
3. Novavax COVID-19 Vaccine, Adjuvanted (2024–2025 Formula)
- Manufacturer: Novavax
- Type: Protein-based vaccine
- Target: Omicron variant KP.2
- Approval Status: Authorized for individuals aged 12 years and older.
Combination Vaccines in Development
mRNA-1083
- Manufacturer: Moderna
- Type: Combination mRNA vaccine targeting both influenza and COVID-19
- Target: COVID-19 and seasonal flu strains
- Development Status: In clinical trials; potential availability by winter 2025–2026.
Summary
The latest COVID-19 vaccines have been updated to better match circulating variants, particularly the Omicron KP.2 strain. The primary vaccines currently in use are:
- Comirnaty (Pfizer-BioNTech)
- Spikevax (Moderna)
- Novavax COVID-19 Vaccine, Adjuvanted